MARKET

ZYME

ZYME

Zymeworks
NYSE

Real-time Quotes | Nasdaq Last Sale

31.10
+0.25
+0.81%
After Hours: 31.50 +0.4 +1.29% 16:21 09/22 EDT
OPEN
31.10
PREV CLOSE
30.85
HIGH
31.99
LOW
30.51
VOLUME
314.85K
TURNOVER
--
52 WEEK HIGH
59.03
52 WEEK LOW
24.82
MARKET CAP
1.44B
P/E (TTM)
-7.1534
1D
5D
1M
3M
1Y
5Y
We're Not Worried About Zymeworks' (NYSE:ZYME) Cash Burn
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Simply Wall St. · 5d ago
Zymeworks' Zanidatamab Aces Mid-Stage Esophageal Cancer Trial
Benzinga · 6d ago
BRIEF-Zymeworks Presents Positive Phase 2 For Gastroesophageal Adenocarcinoma Treatment
reuters.com · 6d ago
Zanidatamab Phase 2 Clinical Trial Demonstrates Promising Response Rate and Durability in First-Line HER2-Positive Gastroesophageal Adenocarcinoma (GEA) at the European Society for Medical Oncology (ESMO) Annual Congress
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that new clinical data for zanidatamab, a HER2'targeted bispecific antibody, demonstrate promising response rates and durabi...
Business Wire · 6d ago
Zymeworks Says Mid-Stage Study Shows Anti-Tumor Activity of Gastroesophageal Cancer Drug Candidate
MT Newswires · 09/13 05:30
Zymeworks Announces Abstract for Zanidatamab in First-line HER2-Expressing Gastroesophageal Cancers (GEA) at the European Society for Medical Oncology (ESMO) Annual Congress
VANCOUVER, British Columbia, September 12, 2021--This press release announces the availability of an abstract that Zymeworks is presenting at the upcoming ESMO Congress
Business Wire · 09/12 22:49
Michael Burry Is Selling These 15 Stocks
In this article, we discuss the 15 stocks Michael Burry is selling. If you want to skip our detailed analysis of these stocks, go directly to Michael Burry Is Selling These 5 Stocks. Hedge fund managers famous for their short-selling exploits have had an e...
Insider Monkey · 09/03 16:23
TetraScience R&D Data Cloud Selected by Leading Clinical-Stage Biotechnology Company
/PRNewswire/ -- , the R&D Data Cloud company, announced today that Zymeworks Inc. has selected the Tetra Data Platform (TDP) to standardize and automate scientific data flow. As a clinical-stage biopharmaceutical company dedicated to the development of nex...
PR Newswire - PRF · 08/31 12:00
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ZYME. Analyze the recent business situations of Zymeworks through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 10 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ZYME stock price target is 51.32 with a high estimate of 74.00 and a low estimate of 36.00.
EPS
Institutional Holdings
Institutions: 160
Institutional Holdings: 37.69M
% Owned: 81.25%
Shares Outstanding: 46.39M
TypeInstitutionsShares
Increased
34
4.71M
New
7
207.60K
Decreased
45
3.91M
Sold Out
22
1.66M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.19%
Pharmaceuticals & Medical Research
-0.16%
Key Executives
Chairman/Director
Lota Zoth
President/Chief Executive Officer/Co-Founder/Director
Ali Tehrani
Chief Financial Officer/Executive Vice President/Primary Contact
Neil Klompas
Executive Vice President/Chief Scientific Officer
Anthony Polverino
Other
Neil Josephson
No Data
About ZYME
Zymeworks Inc. a clinical-stage biopharmaceutical company that is engaged in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer in Canada. The Company operates through a number of platforms, including Azymetric, which is a bispecific platform enables therapeutic antibodies to simultaneously bind multiple distinct locations on a target or to multiple targets; ZymeLink, which is an antibody-drug conjugate (ADC) platform comprised of cytotoxins and the linker technology used to couple these cytotoxins to tumor-targeting antibodies or proteins, and EFECT, which enables finely tuned modulation (both up and down) of immune cell recruitment and function. Its lead product candidate is ZW25, a bispecific antibody that targets two distinct domains of the human epidermal growth factor receptor 2 (HER2). It product candidate ZW49, combines the design of ZW25 with its ZymeLink ADC platform, comprised of its cytotoxin and cleavable linker.

Webull offers kinds of Zymeworks Inc stock information, including NYSE:ZYME real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ZYME stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ZYME stock methods without spending real money on the virtual paper trading platform.